TABLE 1

AEs in MEDI8852 and oseltamivir-only recipients

Type of AENo. (%) of AEsa
Cohort 1: 750 mg MEDI8852 + OS (n = 31)Cohort 2: 3,000 mg MEDI8852 + OS (n = 31)Cohort 3: placebo + OS (n = 32)Cohort 4: 3,000 mg MEDI8852 (n = 31)Cohorts 1, 2, and 4 combined: total MEDI8852 (n = 93)
Any11 (35.5)16 (51.6)10 (31.3)12 (38.7)39 (41.9)
Investigational product related4 (12.9)6 (19.4)5 (15.6)4 (12.9)14 (15.1)
Grade 303 (9.7)2 (6.3)03 (3.2)
SAE01 (3.2)1 (3.1)01 (1.1)
AESI (i.e., infusion-related reaction)01 (3.2)001 (1.1)
Occurring in ≥4% of subjects in any cohort
    Bronchitis4 (12.9)5 (16.1)1 (3.1)2 (6.5)11 (11.8)
    Nausea2 (6.5)1 (3.2)2 (6.3)1 (3.2)4 (4.3)
    Diarrhea02 (6.5)02 (6.5)4 (4.3)
    Upper respiratory tract infection1 (3.2)3 (9.7)004 (4.3)
    Pharyngitis2 (6.5)01 (3.1)1 (3.2)3 (3.2)
    Dysgeusia1 (3.2)2 (6.5)1 (3.1)03 (3.2)
    Bronchial hyperreactivity2 (6.5)0002 (2.2)
    Paresthesia002 (6.3)00
  • a OS, oseltamivir.